This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| H |
HORMONAL PRODUCTS (excluding sex hormones) |
| H1A |
ACTH
Human adrenocorticotrophin hormone (ACTH, corticotrophin) stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. ACTH also maintains adrenal cortex morphology. |
| H3A |
THYROID HORMONE
The two hormones, thyroxine and triiodothyronine, are essential for normal growth and development and also play an important role in energy metabolism. Deficiency of these hormones is involved in hypothyroidism (myxoedema), cretinism and goitre. Human thyroid preparations are now being investigated as are thyrotrophin releasing hormone (protirelin) analogues. |
| H3B |
ANTITHYROID
Hyperthyroidism is the excessive secretion of thyroid hormones. The major forms of thyroid hyperfunction are Graves' disease and Plummer's disease. |
| H4B |
PROSTAGLANDIN
The eicosanoids are formed from certain polyunsaturated fatty acids — principally arachidonic acid — and include the prostaglandins, prostacyclins, thromboxane A2 and the leukotrienes. A number of prostaglandin (PG) analogues are under development. |
| H4C |
RELEASING HORMONE
Releasing hormones stimulate the secretion of pituitary hormones and include thyrotrophin-releasing hormone (TRH), luteinising hormone-releasing hormone (LHRH), growth hormone-releasing hormone (GHRH) and corticotropin-releasing hormone (corticoliberin; CRH). |
| H4D2 |
ANTIPROLACTIN
The control of hyperprolactinaemia is important for the maintainence of normal reproductive function. New products include D2-receptor agonists and ergot alkaloid derivatives. |
| H4E1 |
INSULIN
Human insulins and encapsulated insulin-producing cells are under development for use in diabetes. |
| H4E2 |
GLUCAGON
New glucagon preparations under development include intranasal formulations for the treatment of hypoglycaemia. |
| H4F1 |
GROWTH HORMONE
Human growth hormone (recombinant somatropin or synthetic somatrem) formulations and insulin-like growth factors (IGF-1 and IGF-2) — which appear to function as principal mediators of the action of growth hormone — are in development. |
| H4F2 |
SOMATOSTATIN
Somatostatin analogues that inhibit the secretion of all the hormones of the pancreas (eg insulin, glucagon), growth hormone and thyroid-stimulating hormone (TSH) from the pituitary, and most gastrointestinal peptide hormones. |
| H4Z |
HORMONE
Hormones or hormone-related products (excluding sex hormones) which are not covered by any other category. Products which act on the parathyroid glands and also calcitonin preparations, which regulate calcium concentrations. |
Dialog1
Support Home
View the PDF version of this document